Apricus Biosciences Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Apricus Biosciences

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: phoenix_rising	11/5/2015 7:40:47 PM
	Read Replies (2) of 2026

I find this interesting from page 8 of the 10Q. I must admit, I struggle to see how they can achieve all of this only using the Aspire option since they have already used up the equity financing now. Possibly it is due to the amounts they know they are due to receive for RTD success. "Between the $10.0 million borrowed from the Lenders, the access to additional capital under its committed equity financing facility, the $10.9 million received from the Company’s February 2015 financing, and cash received from Vitaros ® royalties and product sales, the Company believes it has sufficient cash reserves and access to cash to fund its base operations through the fourth quarter of 2016. This includes the completion of its fispemifene phase 2b clinical trial, support of the commercialization of Vitaros®, and other general operating activities."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next